Table 4.
Immunohistochemistry tumor analysis (n = 85).
| IHC Analysis | n (%) |
|---|---|
| PD-L1 CPS a | |
| Negative, <1% | 70 (82.4) |
| Positive, >1% | 15 (17.6) |
| MMR deficient | |
| MSH-2 | |
| Intact | 84 (98.8) |
| Lost | 1 (1.2) |
| MSH-6 | |
| Intact | 84 (98.8) |
| Lost | 1 (1.2) |
| PMS-2 | |
| Intact | 78 (91.8) |
| Lost | 7 (8.2) |
| HER2 | |
| Negative | 77 (90.6 |
| Positive | 8 (9.4) |
| CISH-EBER1 | |
| Negative | 66 (70.2) |
| Positive | 19 (20.2) |
| COX-2 staining intensity | |
| Negative | 4 (4.7) |
| Low to moderate | 68 (80.0) |
| High | 13 (15.3) |
| MUC1 staining intensity | |
| Low to moderate | 15 (17.6) |
| High | 70 (82.4) |
| TA-MUC1 | |
| Negative | 8 (9.4) |
| Positive | 77 (90.6) |
a PDL-1 expression combined positive score (CPS) positive when >1% of tumor cells or >1% of immune cells. Abbreviations: PD-L1 program death-ligand 1; IHC immunohistochemistry; MMR mismatch repair, MSH-2 MutS protein homolog 2, MSH-6 MutS protein homolog 6, PMS-2 postmeiotic segregation increased 2; HER2 human epidermal growth factor receptor 2; CISH chromogenic in situ hybridization; EBER1 Epstein-Barr virus-encoded small ribonucleic acid 1; COX-2 cyclooxygenase 2; MUC1 mucin 1; TA-MUC1 tumor-associated MUC1.